CD4+ T cells are activated via recognition of exogenous derived antigen loaded in major histocompatibility complex (MHC) class II, whereas CD8+ T cells via endogenous derived antigen loaded in MHC class I. For tumor cell killing anti-tumor immune responses rely on the induction of cytotoxic CD8+ T cells for which DCs need to shuttle endocytosed particles into the cross-presentation pathway to load tumor-derived epitopes into MHC class I 4. This evidence concerns the gene CD4 and neoplasm.